TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics ...

Regeneron Pharmaceuticals already has a presence in immunology, but nothing in its portfolio or pipeline addresses inflammatory bowel disorders nor does the drugmaker have any cell therapies. The ...

A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

Understanding how regulatory T cells (Tregs) develop and work is key to determining how they might be manipulated to encourage the destruction of cancer cells or prevent autoimmunity. Cell behavior is ...

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor. Colorectal cancer, however ...

Sonoma Biotherapeutics launched with a mission to create regulatory T-cell treatments for autoimmune and neurodegenerative diseases, $40 million in series A financing and renowned immunologist, ...

California biotech Sangamo Therapeutics has given its first doses of an experimental cell therapy. The company is developing a new type of medicine for autoimmune diseases called CAR-Tregs. Its ...

Prakash Nagarkatti receives funding from the National Institutes of Health. Mitzi Nagarkatti receives funding from the National Institutes of Health. A special group of immune cells known as ...

Recent research from Houston Methodist Hospital showed that a new immunotherapy was safe for patients with ALS and also revealed surprising results that could bring hope to patients who have this ...